Raymond James & Associates Purchases 41,479 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX)

Raymond James & Associates raised its position in G1 Therapeutics, Inc. (NASDAQ:GTHXGet Rating) by 9.5% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 479,635 shares of the company’s stock after buying an additional 41,479 shares during the period. Raymond James & Associates’ holdings in G1 Therapeutics were worth $5,991,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of GTHX. Woodline Partners LP bought a new position in G1 Therapeutics in the 2nd quarter valued at $8,878,000. Millennium Management LLC boosted its position in G1 Therapeutics by 486.3% in the 2nd quarter. Millennium Management LLC now owns 728,120 shares of the company’s stock valued at $3,597,000 after buying an additional 603,926 shares during the last quarter. Renaissance Technologies LLC bought a new position in G1 Therapeutics in the 2nd quarter valued at $2,292,000. Federated Hermes Inc. boosted its position in G1 Therapeutics by 353.2% in the 2nd quarter. Federated Hermes Inc. now owns 179,472 shares of the company’s stock valued at $887,000 after buying an additional 139,872 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its position in G1 Therapeutics by 91.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 257,912 shares of the company’s stock valued at $1,274,000 after buying an additional 123,346 shares during the last quarter. 53.13% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Mark A. Velleca sold 15,000 shares of the firm’s stock in a transaction on Tuesday, October 18th. The stock was sold at an average price of $11.70, for a total transaction of $175,500.00. Following the sale, the director now owns 116,000 shares of the company’s stock, valued at approximately $1,357,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other G1 Therapeutics news, Director Mark A. Velleca sold 15,000 shares of G1 Therapeutics stock in a transaction dated Tuesday, October 18th. The stock was sold at an average price of $11.70, for a total value of $175,500.00. Following the sale, the director now owns 116,000 shares of the company’s stock, valued at approximately $1,357,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John E. (Jack) Jr. Bailey sold 32,019 shares of G1 Therapeutics stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $5.85, for a total value of $187,311.15. Following the completion of the sale, the chief executive officer now directly owns 281,889 shares in the company, valued at approximately $1,649,050.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,207 shares of company stock valued at $380,476. 8.09% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GTHX. EF Hutton Acquisition Co. I began coverage on G1 Therapeutics in a research report on Thursday, January 5th. They issued a “buy” rating and a $35.00 price target on the stock. Needham & Company LLC reduced their price target on G1 Therapeutics from $32.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, January 3rd. HC Wainwright reduced their price target on G1 Therapeutics from $57.00 to $34.00 in a research report on Wednesday, November 23rd. Finally, Citigroup began coverage on G1 Therapeutics in a research report on Wednesday, January 4th. They issued a “buy” rating on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat, G1 Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $31.25.

G1 Therapeutics Stock Performance

Shares of G1 Therapeutics stock opened at $6.32 on Friday. The company has a market capitalization of $271.19 million, a PE ratio of -1.76 and a beta of 1.64. G1 Therapeutics, Inc. has a 12 month low of $3.84 and a 12 month high of $17.49. The company has a current ratio of 4.24, a quick ratio of 3.86 and a debt-to-equity ratio of 1.67. The stock’s fifty day simple moving average is $6.32 and its 200 day simple moving average is $9.49.

G1 Therapeutics (NASDAQ:GTHXGet Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.05. The business had revenue of $23.58 million for the quarter, compared to the consensus estimate of $22.64 million. G1 Therapeutics had a negative return on equity of 172.97% and a negative net margin of 328.58%. On average, research analysts predict that G1 Therapeutics, Inc. will post -3.49 EPS for the current year.

About G1 Therapeutics

(Get Rating)

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

Recommended Stories

Want to see what other hedge funds are holding GTHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for G1 Therapeutics, Inc. (NASDAQ:GTHXGet Rating).

Institutional Ownership by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.